logo
Plus   Neg
Share
Email

Bombardier Q2 Loss Widens

Bombardier (BBD_B.TO,BBD_A.TO) reported that its second-quarter net loss widened to $223 million from $36 million in the prior year.

Adjusted net loss attributable to equity holders of the company widened to $713 million or $0.30 per share from $101 million or $0.04 per share in the prior year.

Consolidated adjusted EBIT loss of $427 million reflecting charge at Transportation related to legacy projects and COVID-19 impact at both Aviation and Transportation; Reported EBIT of $26 million reflecting an accounting gain on the CRJ divestiture.

Consolidated revenues were $2.7 billion, down 37% year-over-year, reflecting a lower level of production activity and deliveries in the quarter as operations at key Aviation and Transportation sites across North America and Europe were temporarily suspended for several weeks due to the global COVID-19 pandemic.

Bombardier expects sale of its aerostructure business to Spirit AeroSystems Holdings to close this fall.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Amid the growing climate crisis, Walmart said it is raising its ambition to zero emissions by 2040, without the use of carbon offsets, across its global operations. The retail giant, along with the Walmart Foundation, also committed to help protect, manage or restore at least 50 million acres of land and one million square miles of ocean by 2030. The European Commission said Friday that it has signed a deal with Sanofi and GlaxoSmithKline to secure up to 300 million doses of their potential COVID-19 vaccine. Acella Pharmaceuticals recalled certain lots of hypothyroidism medication NP Thyroid in the form of tablets due to super potency, the U.S. Food and Drug Administration said in a statement. The company is recalling one lot of 15mg and one lot of 120mg of NP Thyroid that are packaged in 100 count bottles in strengths of 15 mg, and 120 mg, with expiration dates between October 2020 and November 2020.
Follow RTT